金陵药业股份有限公司 独立董事2024年度述职报告 各位股东及代表： 2023 年 6 月 28 日，金陵药业股份有限公司（以下简称"公司"） 2023 年第二次临时股东大会选举本人高燕萍担任第九届董事会独立 董事。同日召开的公司第九届董事会第一次会议选举本人担任董事会 薪酬与考核委员会的召集人，以及董事会战略委员会委员、提名委员 和审计委员会委员。 2024 年度，本人作为公司的独立董事按照《公司法》《上市公司 治理准则》和《上市公司独立董事管理办法》等法律法规以及《公司 章程》的规定，本着客观、公正、独立的原则，及时了解公司各方面 的经营状况；按时出席公司股东大会和董事会，认真审议董事会各项 议案，对公司相关事项发表独立意见，并对各项议案进行表决，积极 发挥独立董事作用，维护公司整体利益和全体股东尤其是中小股东的 合法权益。 一、独立董事的基本情况 （一）个人简介 本人高燕萍，女，1963 年出生，博士。历任上海复旦医院管理 有限公司副总经理、上海美华医疗集团副总裁、担任瑞典医疗健康发 展集团副总裁、中国上海办事处首席代表、上海歆柏医院管理有限公 司总经理，现任上海康程医院管理咨询有限公司总裁、副董事长、 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0682 | 0.2107 | -67.63 | 0.2089 | | 每股净资产（元） | 6.08 | 6.04 | 0.66 | 5.94 | | 每股公积金(元) | 1.76 | 0.94 | 87.23 | 0.94 | | 每股未分配利润(元) | 2.66 | 3.26 | -18.4 | 3.18 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 32.81 | 31.94 | 2.72 | 26.71 | | 净利润(亿元) | 0.4 | 1.06 | -62.26 | 1.05 | | 净资产收益率(%) | 1.09 | 3.30 | -66.97 | 3.54 | 数据四舍五入，查看更多财务数据>> 10派1元(含税) 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 29652.44万股，累计占流通股 ...

Financial Performance - The company's operating revenue for 2024 reached ¥3,281,450,555, representing a 2.74% increase compared to ¥3,193,999,850 in 2023[21]. - The net profit attributable to shareholders decreased by 61.95% to ¥40,409,795.7 from ¥106,193,864 in the previous year[21]. - The net cash flow from operating activities was ¥154,190,609, down 27.28% from ¥212,024,737 in 2023[21]. - Basic earnings per share fell by 67.63% to ¥0.0682 from ¥0.2107 in 2023[21]. - Total assets increased by 10.86% to ¥6,088,855,020 compared to ¥5,492,591,080 in 2023[22]. - The net assets attributable to shareholders rose by 17.22% to ¥3,791,090,830 from ¥3,234,294,840 in the previous year[22]. - The company achieved total operating revenue of 328,145.06 million yuan and a net profit attributable to the parent company of 4,040.98 million yuan during the reporting period[49]. - The total revenue for the reporting period was ¥3,281,450,554.7, representing a year-on-year increase of 2.74% from ¥3,193,999,854.5[61]. - Revenue from pharmaceutical production and sales decreased by 3.93% to ¥1,493,178,383.1, while medical services revenue increased by 10.83% to ¥1,740,050,342.0[61]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares to all shareholders, based on a total of 623,708,628 shares[3]. - The company reported a cash dividend of 1.00 yuan per 10 shares, totaling 62,370,862.80 yuan for the reporting period[162]. - The cash dividend distribution accounted for 100% of the total profit distribution amount[162]. - The total distributable profit available for shareholders at the end of 2024 is 889,118,106.16 yuan, after accounting for the net profit and dividends paid[164]. - The company’s profit distribution policy was executed in accordance with its articles of association, ensuring the protection of minority shareholders' rights[162]. Business Operations and Changes - The company has undergone business changes, expanding from pharmaceutical manufacturing to include medical services and health care services since 2003[19]. - The company operates in the pharmaceutical and medical device manufacturing sectors, focusing on traditional Chinese medicine and chemical drugs, with key products including "Mailuo Ning Injection" and "Ferrous Succinate Tablets"[43]. - The company has maintained a stable revenue stream, with a low debt ratio and financial leverage, indicating strong financial health[48]. - The company has implemented a management model that integrates investment management and operational oversight across its subsidiaries, ensuring strategic alignment and resource optimization[44]. - The company is actively expanding its healthcare services, including integrated medical and elderly care services, to meet the growing demand in the market[45]. Market Trends and Industry Insights - The pharmaceutical manufacturing industry in China achieved a revenue of ¥3.5 trillion in 2024, growing by 8.5% year-on-year[31]. - The overall medical service market size in 2024 is estimated at 4.8 trillion yuan, reflecting a 9% year-on-year increase[33]. - The elderly medical consumption market size is projected to reach 2.2 trillion yuan in 2024, with a year-on-year growth of 10%[35]. - The number of remote medical service institutions is anticipated to grow by 20% in 2024, reaching 150,000[34]. - Online consultation volume is expected to increase by 30% in 2024, reaching 1 billion consultations[34]. Research and Development - Investment in innovative drug research and development increased to 15% of total revenue, up 2 percentage points from the previous year[31]. - The company invested ¥110,692,200 in research and development during the reporting period, maintaining growth in R&D expenditure[57]. - The company reported a total R&D expenditure of ¥110,692,239.54, an increase of 39.86% compared to ¥79,143,338.26 in the previous year, representing 3.37% of total revenue[75]. - The number of R&D personnel increased by 16.79% to 153, with a notable rise in the number of master's and doctoral degree holders[74]. - The company has a robust drug pipeline, with multiple projects in various stages of development, including drugs for chronic heart failure and advanced breast cancer[58][59]. Acquisitions and Investments - The acquisition of a 51% stake in Nanjing Meishan Hospital was completed, enhancing the company's medical service sector and resolving competition issues with the controlling shareholder[53]. - The company completed a stock issuance to specific investors, with funds received on March 25, 2024, to support key projects[52]. - The company is actively pursuing partnerships and collaborations to enhance its research capabilities and product offerings[56]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting companies with annual revenues of $50 million to $200 million[135]. Governance and Compliance - The company has implemented a governance structure that complies with relevant laws and regulations, enhancing its governance level[114]. - The board of directors operates independently, with independent directors having sufficient access to information to fulfill their duties[115]. - The company has established an independent financial department with a standardized accounting system and separate bank accounts, ensuring independent tax compliance[118]. - The company has disclosed its "Quality and Return Dual Improvement" action plan, indicating a commitment to enhancing quality and returns[112]. - The company has maintained effective internal controls in all significant aspects of financial reporting[174]. Environmental Responsibility - The company has implemented a VOCs "one enterprise, one policy" governance plan since 2021 to improve air quality[191]. - The company has actively participated in the "waste-free factory" initiative and received certification as a "waste-free factory" in Nanjing[190]. - The company paid 11,729.83 yuan in environmental protection tax for the year 2024[190]. - The company has implemented "rainwater and sewage diversion" systems at its facilities to enhance wastewater treatment efficiency[186]. - Jinling Pharmaceutical Factory's average COD discharge concentration in 2024 was 78.3 mg/L, significantly below the limit of 500 mg/L[186]. Employee Management and Training - The total number of employees at the end of the reporting period was 5,789, with 882 in the parent company and 4,907 in major subsidiaries[156]. - The company conducted 1,273 training sessions in 2024, with a total training investment exceeding 5 million yuan, achieving a 100% training coverage rate[159]. - The company has a performance-oriented compensation policy, linking employee salaries to individual, departmental, and overall company performance[158]. - The average training hours per employee were approximately 2 hours, reflecting the company's commitment to talent development[159]. - The company has a diverse management team with various roles, including a total of 8 assistant presidents[140][141].

金陵药业股份有限公司 2024 年度董事会工作报告 公司未来计划、经营计划等前瞻性陈述，不构成公司对投资者的 实质承诺，请投资者注意投资风险。 2024 年，金陵药业股份有限公司（以下简称"公司"）董事会 严格遵守《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《深圳证 券交易所股票上市规则》（以下简称"《股票上市规则》"）、《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》（以下简称"《规范运作》"）、《公司章程》及《董事会议 事规则》等有关法律法规及公司相关制度的规定，依法履行董事会的 各项职责，本着对全体股东负责的态度，规范运作、科学决策，认真 贯彻落实股东大会的各项决议，持续提升公司治理水平，切实维护公 司和全体股东的合法权益，积极有效地发挥了董事会的作用。现将公 司 2024 年度董事会主要工作报告如下： 一、2024 年度董事会任职及运作情况 （一）任职情况 公司第九届董事会下设战略委员会、提名委员会、审计委员会和 薪酬与考核委员会四个专门委员会，任职情况如下： | 序 号 | 专门委员会 | 委 员 | | -- ...

根据《上市公司独立董事管理办法》《深圳证券交易所上市公司 自律监管指引第 1 号——规范运作》的有关规定，独立董事应当每年 对任职独立性进行自查，并将自查情况提交董事会。董事会应当每年 对在任独立董事独立性情况进行评估并出具专项意见。基于此，金陵 药业股份有限公司（以下简称"公司"）董事会根据相关法规并结合 独立董事出具的《金陵药业股份有限公司独立董事独立性自查情况 表》，就公司 2024 年度在任独立董事的独立性情况进行评估，并出 具专项意见。 金陵药业股份有限公司董事会 关于 2024 年度独立董事独立性情况的专项意见 2025 年 3 月 27 日 金陵药业股份有限公司董事会 经公司独立董事高燕萍、沈永建、寇俊萍自查及董事会核查独立 董事在公司的履职情况，董事会认为公司全体独立董事均具备胜任独 立董事岗位的资格。独立董事及其配偶、父母、子女、主要社会关系 未在公司或公司附属企业任职，未在公司主要股东及其附属企业任职， 未与公司存在重大的持股关系，与公司及主要股东之间不存在重大业 务往来关系或提供财务、法律、咨询、保荐等服务关系。 因此，公司独立董事高燕萍、沈永建、寇俊萍不存在任何妨碍其 进行独立客观判断 ...

金陵药业股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：陈胜 主管会计工作负责人：汪洋 会计机构负责人：费超 编制单位：金陵药业股份有限公司 单位：万元 本表已于 2025 年 3 月 27 日获董事会批准。 | 南 京 鼓 楼 | | 应收账款 | - | 5.19 | - | 2.46 | 2.73 | 销售 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 医 院 集 团 | 子公司 | | | | | | | | | | 宿 迁 医 院 | | 其他应收款 | 27.16 | 28.22 | - | 27.16 | 28.22 | 往来 | 经营性往来 | | 有限公司 | | | | | | | | | | | 南 京 鼓 楼 | | 应收账款 | 4.30 | 4.64 | - | 8.94 | - | 销售 | 经营性往来 | | 医 院 集 团 | | | | | | | | | | | 安 庆 市 石 | 子公司 | 其他应收款 | 61.42 | 33. ...

金陵药业股份有限公司 二 O 二四年度财务决算报告 公司二○二四年度会计报表已经立信会计师事务所（特殊普通合伙）审计， 并出具了《审计报告》【信会师报字[2025]第ZH10009号】。审计报告认为：公 司财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了公司2024 年12月31日的合并及母公司财务状况以及2024年度的合并及母公司经营成果和 现金流量。 现将公司二○二四年度财务决算情况报告如下： 一、公司分支机构及子公司情况 （一）期末公司分支机构情况 金陵药业股份有限公司（母公司，以下简称公司），其下设分支机构包括技 术中心、南京金陵制药厂、福州梅峰制药厂、浙江天峰制药厂和合肥分公司。 （二）期末公司子公司情况 本公司 2024 年度纳入合并范围的子公司共 22 户。详见下表： | 序号 | 子公司名称 | 子公司 | 级次 | 持股比例（%） | | | --- | --- | --- | --- | --- | --- | | | | 类型 | | 直接 | 间接 | | 1 | 云南金陵植物药业股份有限公司 | 控股 | 一级 | 88.89 | 4.44 | | 2 | 河南金陵怀药有 ...